Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal)
Technology appraisal
Reference number: TA1068
Published:
Please note that following an update from the company the timelines for this appraisal are anticipated to begin in mid-October 2024 when we will write to you about how you can get involved.